2PHARMA
ActiveSummary
2PHARMA has been active since 2007 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €779,467 and a net result of €120,628. Equity is growing by about 15% per year across the filed financial years. Its solvency ranks better than 76% of 6,075 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Directors
Board 3
Day-to-day management 1
Permanent representatives 3
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| Aquitania |
|
| MD CONSULT |
|
| SDV Consult |
|
Owners and capital
Owners
1 ownerChain of control
- Ceres Invest
- Ceres Pharma
- 2PHARMA HOLDING
- 2PHARMA
Highest known parent: Ceres Invest. The sources do not say who stands above it.
Owners 1
- 2PHARMA HOLDINGparent100%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- 29-04-2026 Capital stated in the deed · €375,000 · 1,250 shares